For immediate release: June 10, 2014
Contact: Britten Pund, 202-434-8044, bpund@NASTAD.org
Washington, DC – Today, the National Alliance of State & Territorial AIDS Directors (NASTAD) released the 2014 Online AIDS Drug Assistance Program (ADAP) Formulary Database (the Database) and accompanying User’s Guide. The Database details ADAP coverage of medications both individually and by drug class, marking the first time state-by-state ADAP formulary coverage data has been made publicly available in an online searchable format. NASTAD receives frequent requests regarding individual states’ formulary composition. This newly-released online format provides a method to query this data. Medications included in the Database include antiretroviral (ARV) treatments and “A1” Opportunistic Infections (A1 OI) medications, as well as treatments for hepatitis B and C, substance use treatment medications and various vaccines and laboratory tests. The Database includes formulary information from all 50 states as well as the District of Columbia, Guam and Puerto Rico, as of March 31, 2014. Moving forward, the Database will be updated as new information becomes available. In addition, interested parties are encouraged to contact individual ADAPs with specific questions about medication availability. Continue reading
By Christopher Cannon, Manager, Health Care Access, NASTAD
http://www.nikeairmaxfreedom.com air max
Prior to the approval of Truvada as PrEP, health departments feared there would be a rush of affluent gay men demanding access to Pre-Exposure Prophylaxis (PrEP)-the use of antiretroviral medication to prevent the infection of HIV-to abandon condom use altogether. In so doing, they would create greater health disparities among vulnerable populations like young gay and bisexual men, Black and Latino gay and bisexual men, and transgender women who are often disenfranchised. However interest in PrEP outside of clinical trials across the country has been very limited. Gilead, manufacturer of Truvada, reports only 2,319 prescriptions filled for Truvada as PrEP from January 1, 2012 (prior to FDA approval in July 2012) to September 30, 2013 in the United States, which currently has an estimated 50,000 HIV infections each year. Continue reading
June 16, 2014 – This month, as part of on-going efforts to explore and address community- and institution-level stigma impacting Black and Latino gay men and MSM within public health practice, the National Alliance of State and Territorial AIDS Directors (NASTAD) and the National Coalition of STD Directors (NCSD) are re-launching an updated survey assessment to continue efforts to monitor stigma in public health practice. Through support from the MAC AIDS Fund, NASTAD and NCSD conducted a three-year study of stigma and its impact on public health practice for Black and Latino gay men/MSM. This work included a national survey of more than 1,300 respondents; the convening of a Blue Ribbon Panel of stakeholders and medical providers; the publication of “Optimal Care Checklists” for providers and for Black and Latino gay male patients; and the convening of a National Stigma Summit on Black and Latino Gay Men’s Health. Continue reading
June 11, 2014 – The National Alliance of State and Territorial AIDS Directors (NASTAD) and the National Coalition of STD Directors (NCSD) are launching “Addressing Stigma: A Blueprint for HIV/STD Prevention and Care Outcomes for Black and Latino Gay Men.” The blueprint contains 17 recommendations for reducing public health stigma that prevents Black and Latino gay men and other men who have sex with men (MSM) from receiving optimal health care. Health departments will receive four courtesy copies via mail to distribute across programs (i.e., HIV prevention and care, STD programs).
By Dawn Fukuda, Director, Office of HIV/AIDS, Massachusetts Department of Public Health and NASTAD Chair (Outgoing)
Director, Office of HIV/AIDS, Massachusetts Department of Public Health and NASTAD Chair
As I began my tenure as chair of the National Alliance of State and Territorial AIDS Directors (NASTAD) in May 2013, I was full of energy and optimism. January 1st of 2014 was close at hand, and represented a massive new opportunity to invigorate our response to the HIV and viral hepatitis epidemics through the implementation of the Affordable Care Act (ACA).
I was confident based on our experience with state health care reform in my home state of Massachusetts that increased access to medical care through broader insurance coverage would translate into health promotion and disease prevention outcomes that would advance our progress along the HIV Care Continuum. I remain steadfast in my belief that integrating an HIV and viral hepatitis response into primary medical care and reimbursable health services is the way to sustain our efforts into the future; yet the mechanics of the ACA roll out over the past year also provide a striking reminder of the essential and non-transferrable role of public health.